DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies

Citation for published version:

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Peer reviewed version

Published in:
Journal of Virology

Publisher Rights Statement:
Copyright © 1998, American Society for Microbiology. All Rights Reserved.
DNA Vaccination Affords Significant Protection against Feline Immunodeficiency Virus Infection without Inducing Detectable Antiviral Antibodies

MARGARET J. HOSIE,* J. NORMAN FLYNN, MARK A. RIGBY, CELIA CANNON, THOMAS DUNSFORD, NANCY A. MACKAY, DAVID ARGYLE, BRIAN J. WILLETT, TAKAYUKI MIYAZAWA,† DAVID E. ONIONS, OSWALD JARRETT, AND JAMES C. NEIL

Retrovirus Research Laboratory, Department of Veterinary Pathology, University of Glasgow, Bearsden, Glasgow G61 1QH, United Kingdom.

Received 18 February 1998/Accepted 19 May 1998

To test the potential of a multigene DNA vaccine against lentivirus infection, we generated a defective mutant provirus of feline immunodeficiency virus (FIV) with an in-frame deletion in pol (FIVΔRT). In a first experiment, FIVΔRT DNA was administered intramuscularly to 10 animals, half of which also received feline gamma interferon (IFN-γ) DNA. The DNA was administered in four 100-μg doses at 0, 10, and 23 weeks. Immunization with FIVΔRT elicited cytotoxic T-cell (CTL) responses to FIV Gag and Env in the absence of a serological response. After challenge with homologous virus at week 26, all 10 of the control animals became seropositive and viremic but 4 of the 10 vaccinates remained seronegative and virus free. Furthermore, quantitative virus isolation and quantitative PCR analysis of viral DNA in peripheral blood mononuclear cells revealed significantly lower virus loads in the FIVΔRT vaccinates than in the controls. Immunization with FIVΔRT in conjunction with IFN-γ gave the highest proportion of protected cats, with only two of five vaccinates showing evidence of infection following challenge. In a second experiment involving two groups (FIVΔRT plus IFN-γ and IFN-γ alone), the immunization schedule was reduced to 0, 4, and 8 weeks. Once again, CTL responses were seen prior to challenge in the absence of detectable antibodies. Two of five cats receiving the proviral DNA vaccine were protected against infection, with an overall reduction in virus load compared to the five infected controls. These findings demonstrate that DNA vaccination can elicit protection against lentivirus infection in the absence of a serological response and suggest the need to reconsider efficacy criteria for lentivirus vaccines.

The continued spread of human immunodeficiency virus (HIV) worldwide makes the development of an effective vaccine an urgent priority for world health. However, HIV and its animal lentivirus counterparts present formidable challenges for vaccine development because they cause persistent infection and induce disease despite a vigorous host immune response (8). Among the available animal analogs of HIV, feline immunodeficiency virus (FIV) has unique value as a widespread naturally occurring infectious agent in its natural host (45). Conventional approaches to vaccine development have been pursued extensively for FIV and simian immunodeficiency virus (SIV) but have yielded only qualified successes. Whole inactivated virus vaccines have proved effective in the FIV model, and protection is virus specific (48) but limited to the homologous virus and may depend on a fortuitous vaccine strain of virus which elicits strong neutralizing-antibody responses (16). Subunit vaccines based on purified or recombinant Env glycoproteins have given some evidence of protection against HIV in a small number of chimpanzees, but similar SIV or FIV vaccines have led at best to reduced virus loads after challenge and in some instances to enhancement of infection (17, 22, 40). More robust resistance has been observed to SIV after infection with attenuated strains lacking regulatory genes such as nef (6), but safety fears make the use of this approach in humans controversial (3, 46).

DNA-mediated immunization has emerged recently as a promising alternative approach to the development of viral vaccines, with protective immunity against viral infections such as avian influenza (33), Newcastle disease (36), and Aujeszky’s disease (13), as well as a wide range of nonviral pathogens (reviewed in reference 42), being generated following in vivo administration of naked DNA to muscle or skin. Given that antiretroviral therapy is unlikely to be economically viable in developing countries, a further attraction of DNA-mediated immunization is the prospect of stable and affordable vaccines.

Several HIV-1 DNA constructs induce immune responses in mice and primates (25, 38, 43), and forthcoming phase I trials will assess the safety and immunogenicity of HIV-1 env DNA in human subjects. Encouraging evidence for the use of DNA vaccines was described recently when an HIV-1 DNA vaccine containing env, rev, and gag/pol induced protective immunity in the chimpanzee model (4). However, since HIV-1 is apathogenic in the chimpanzee model system, the question arises whether similar approaches will be effective in inducing protection against lentivirus infection in the natural host species that are susceptible to virus-induced disease, such as FIV in the domestic cat.

In this study, we generated an FIV DNA vaccine construct based on a replication-defective but essentially full-length proviral genome which should express both structural and regulatory proteins in vivo. We investigated the efficacy of this FIV DNA vaccine and demonstrated that a significant proportion of the cats vaccinated with this DNA were protected from subsequent challenge with the homologous virus. Further-
more, the protective effect was retained in a second trial involving a much shorter immunization schedule. This study provides the first evidence that DNA-mediated immunization can prevent lentivirus infection in its natural host species.

MATERIALS AND METHODS

Cells and viruses. Cell culture media and supplements were obtained from Life Technologies Inc., Paisley, United Kingdom. Crandell feline kidney (C свойства) cells (5) were maintained in Dulbecco's modification of minimal essential medium Eagle supplemented with 10% heat-inactivated fetal bovine serum, 2 mM glutamine, 0.11 mg of sodium pyruvate per ml, 100 μg of streptomycin per ml, and 100 IU of penicillin per ml. MYA-1 cells (27) were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 2 mM glutamine, 100 IU of penicillin per ml, 100 μg of streptomycin per ml, 5 × 10⁻⁵ M 2-mercaptoethanol (complete RPMI 1640 medium). Human interleukin-2 (IL-2) gene and which produces high levels of human IL-2 (addition of 2% supernatant was found to be equivalent to addition of approximately 100 IU of recombinant human IL-2). The IL-2-like 2.23 cell line was a kind gift of M. Hattori, University of Tokyo. The FIV-PE7 challenge virus was prepared as described previously (32) by transfection of the murine fibroblast cell line NIH 3T3 with the FIV molecular clone of FIV-PE7 (28) and recovery into the IL-2-dependent feline T-cell line Q206 (44).

Preparation of DNA immunogens. The reverse transcriptase (RT) deletion mutant FIVART was prepared from the F-14 molecular clone of FIV-PE7 (28). Cloning and characterization of feline gamma interferon (IFN-γ) have been described previously (1). For use as an adjuvant gene, the IFN-γ cDNA was subcloned into the pCR-3-RSV vector (Invitrogen BV, De Schelpe, The Netherlands) as a HindIII-NotI fragment.

Plasmid DNAs were purified by cesium chloride-ethidium bromide gradient centrifugation followed by butanol extraction and ethanol precipitation. Following resuspension in 10 mM Tris plus 1 mM EDTA, the plasmids were dialyzed extensively against phosphate-buffered saline (PBS). Endotoxin levels were quantified commercially by Q1 Biotech, Glasgow, United Kingdom, by the Limulus amebocyte lysate technique and were found to be <0.5 EU/ml.

DNA immunization and virus challenge. Kittens (12 weeks old) were randomized into groups of five for immunization. DNA was administered at four sites in the gastrocnemius and quadriceps muscles (100 μg of each DNA in a total of 200 μl of PBS at each site). The cats were challenged with the homologous FIV-14 molecular clone of the FIV-PE7 isolate that had been subjected to titer determination by intraperitoneal inoculation of age-matched cats to calculate the 50% infectious dose.

Detection of FIV-specific CTL. Lymphocytes were collected from peripheral blood as described previously (10) and assayed directly for cytotoxic T-lymocyte (CTL) activity. Target cells were autologous or allogeneic skin fibroblasts derived from biopsy material collected prior to vaccination (9). The target cells were labeled with 51Cr and infected with recombinant vaccinia virus expressing FIV Gag (10) or Env (41) or wild-type vaccinia virus as a control. Effector/target (E/T) ratio of 50:1, and lytic activity was measured by monitoring isotope release as described previously (10).

Serological tests. Plasma samples were tested for the presence of anti-FIV antibodies by immunoblot analysis as described previously (19). Peptide-based enzyme-linked immunosorbent assays (ELISA) were used to determine titers of antibody recognizing an immunodominant epitope expressed on FIV Gag (10) or Env (41) or wild-type vaccinia virus as a control. Effector cells (>99% viable) were added at an effector-to-target-cell (E/T) ratio of 50:1, and lytic activity was measured by monitoring isotope release as described previously (10).

RESULTS

Generation of a replication-defective FIV vaccine construct (FIVART). The F-14 molecular clone of FIV-PE7 has previously been shown to be infectious for cats following intramuscular injection of plasmid DNA (32). To render the FIV provirus noninfectious while leaving as much as possible of the coding potential intact, deletions were generated around a PacI restriction site located within the RT coding sequence at the hinge between the RT and RNase H domains (28). From a library of clones generated by sequential PacI and BalI digestion and religation, we selected a recombinant which had sustained a 33-codon deletion. The precise boundaries of this deletion are shown in Fig. 1a below a partial restriction map of the F-14 proviral clone (28). Characterization of this deletion mutant has shown that it is completely defective with respect to virion infectivity and RT activity. However, transfection studies
showed that FIV\textsuperscript{ART} is essentially normal in Env-mediated cell fusion and viral antigen release (data not shown). As shown in Fig. 2, CrFK cells transfected with FIV\textsuperscript{ART} and the parental F-14 clone release similar levels of viral proteins. The FIV\textsuperscript{ART}-derived virions showed a consistent reduction in the extent of Gag protein processing, suggesting some impairment of Gag-Pol precursor transport or function, but since authentic processing was clearly occurring, this proviral construct was adopted as the basis of the FIV\textsuperscript{ART} DNA vaccine.

DNA vaccination with FIV\textsuperscript{ART} induces a virus-specific CTL response. In the first vaccine trial of FIV\textsuperscript{ART}, three groups of five cats were immunized with DNA comprising either FIV\textsuperscript{ART}, FIV\textsuperscript{ART} in conjunction with IFN-\(\gamma\), or IFN-\(\gamma\) alone. A fourth control group received no DNA. A line diagram depicting the schedule is shown in Fig. 3. Virus-specific CTL responses were first detected in unstimulated peripheral blood three weeks following the first immunization. Gag- and Env-specific CTL responses were observed in all cats immunized with FIV\textsuperscript{ART} (Fig. 4a), although the magnitude of the response varied between individual animals, as might be expected given the outbred nature of the study population, with higher levels of \(^{51}\text{Cr}\) release observed in cats A481 to A483 than in cats A484 and A485. However, in all cats the observed lysis exceeded 10% at an E/T ratio of 50:1. The CTL activity was not observed when allogeneic target cells were used in the assay, suggesting that the observed activity was major histocompatibility complex restricted. There was also no recognition of autologous target cells infected with wild-type vaccinia virus, confirming the specificity of the response.

Coimmunization with FIV\textsuperscript{ART} and IFN-\(\gamma\) DNA also elicited FIV Gag- and Env-specific CTL responses in the unstimulated PBMC of all cats, and in some of these animals higher levels of \(^{51}\text{Cr}\) release were detected than in cats inoculated with FIV\textsuperscript{ART} alone (Fig. 4b). However, these responses were not entirely major histocompatibility complex restricted since lysis of allogeneic target cells was also observed. The nonspecific nature of the cytolytic responses observed following IFN-\(\gamma\) DNA immunization was also indicated by the recognition of autologous target cells infected with wild-type vaccinia virus. Furthermore, immunization with IFN-\(\gamma\) DNA alone resulted in the induction of CTL responses recognizing either autologous or allogeneic target cells or target cells infected with wild-type vaccinia virus (Fig. 4c), suggesting that in vivo delivery of the feline IFN-\(\gamma\) plasmid may have stimulated a nonspecific cellular immune response. No FIV-specific CTL activity was observed in control cats inoculated with PBS alone (Fig. 4d).

Analysis of the CTL response 6 weeks after the initial immunization revealed a general decline in activity (Fig. 5). This was most marked in the group coimmunized with FIV\textsuperscript{ART} and IFN-\(\gamma\), in which no CTL activity could be detected. In the FIV\textsuperscript{ART}-immunized group, although Gag- and Env-specific CTL responses were still detectable in four of five cats, the levels of lysis were lower than those observed at week 3. In two of five cats (A481 and A482) in the FIV\textsuperscript{ART} group and three of five cats (A487, A488, and A489) in the FIV\textsuperscript{ART}-plus-IFN-\(\gamma\)-coimmunized group, this activity remained at background levels despite repeat inoculations of DNA. In contrast, a transient boosting of FIV Gag-specific CTL activity was observed in the remaining five cats at week 12, 2 weeks after the repeat DNA inoculation administered at week 10, and in one animal (A490) a transient increase in Env-specific CTL activity was observed before the level declined to background levels (Fig. 6). Further boosting at week 23 had a negligible effect on the FIV-specific effector CTL responses detected in the peripheral blood (data not shown), and all cats were challenged at week 26.

DNA immunization does not induce antiviral antibodies. In contrast to the CTL responses, FIV-specific antibodies were not detected by any available test, including ELISA for the immunodominant TM peptide and immunoblot analysis with a lysate of FIV-PET-infected cells (Table 1). Previous studies by us and others have demonstrated these assays to be reliable and sensitive measures of FIV-specific serological responses in naturally infected cats (19, 39). Similarly, no virus-neutralizing antibodies were detected in plasma samples taken on the day of challenge.

FIV\textsuperscript{ART} vaccine affords protection against challenge with infectious FIV. In view of the apparent refractory immune state of the vaccinated cats, we decided to test their ability to resist viral infection. All 20 cats were challenged at week 26 with the homologous FIV-PET isolate by intraperitoneal inoculation of 25 50% infectious doses. The cats were monitored following challenge for the presence of infectious FIV and viral DNA and for evidence of seroconversion.

Virus isolation was attempted at 0, 3, 6, 9, and 12 weeks following challenge. Virus was isolated from 5 of 10 control cats by week 3 postchallenge, as well as from 2 of 5 cats inoculated with FIV\textsuperscript{ART}. In contrast, all of the cats inoculated with FIV\textsuperscript{ART} plus IFN-\(\gamma\) remained virus free at this time, indicating that either their viral loads were below the detection limit of the assay or infection was delayed in this group (Table 1). At 6, 9, and 12 weeks postchallenge, one of five FIV\textsuperscript{ART} vaccinates and three of five FIV\textsuperscript{ART}-plus-IFN-\(\gamma\) vaccinates were expected given the outbred nature of the study population, with higher levels of \(^{51}\text{Cr}\) release observed in cats A481 to A483 than in cats A484 and A485. However, in all cats the observed lysis exceeded 10% at an E/T ratio of 50:1. The CTL activity was not observed when allogeneic target cells were used in the assay, suggesting that the observed activity was major histocompatibility complex restricted. There was also no recognition of autologous target cells infected with wild-type vaccinia virus, confirming the specificity of the response.

Coimmunization with FIV\textsuperscript{ART} and IFN-\(\gamma\) DNA also elicited FIV Gag- and Env-specific CTL responses in the unstimulated PBMC of all cats, and in some of these animals higher levels of \(^{51}\text{Cr}\) release were detected than in cats inoculated with FIV\textsuperscript{ART} alone (Fig. 4b). However, these responses were not entirely major histocompatibility complex restricted since lysis of allogeneic target cells was also observed. The nonspecific nature of the cytolytic responses observed following IFN-\(\gamma\) DNA immunization was also indicated by the recognition of autologous target cells infected with wild-type vaccinia virus. Furthermore, immunization with IFN-\(\gamma\) DNA alone resulted in the induction of CTL responses recognizing either autologous or allogeneic target cells or target cells infected with wild-type vaccinia virus (Fig. 4c), suggesting that in vivo delivery of the feline IFN-\(\gamma\) plasmid may have stimulated a nonspecific cellular immune response. No FIV-specific CTL activity was observed in control cats inoculated with PBS alone (Fig. 4d).

Analysis of the CTL response 6 weeks after the initial im-

FIG. 2. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of sedimented virus particles released from FL4 cells persistently infected with FIV-PET (lane 1), mock-transfected CrFK cells (lane 2), CrFK cells transfected with the F-14 molecular clone (lane 3), and CrFK cells transfected with the FIV\textsuperscript{ART} construct (lane 4).
remained virus free. In contrast, virus was isolated consistently from all of the control cats (IFN-γ alone and no-DNA control groups) at 6, 9, and 12 weeks postchallenge.

Since all of the cats were seronegative on the day of challenge, positive immunoblot results and titers of antibodies recognizing the TM peptide indicated infection. The results of serological tests confirmed previous observations that immunoblot analysis is the more sensitive indicator of infection in cats infected with FIV-PET (18, 32), since not all of the infected and immunoblot-positive cats developed detectable titers of anti-FIV TM peptide antibodies by week 12 postchallenge (Table 1). Furthermore, the immunoblot results correlated closely with virus isolation results. Plasma from the four cats which were virus isolation negative remained negative throughout the experiment (Fig. 7). In contrast, the control groups which received IFN-γ alone or PBS all became seropositive by 6 weeks postchallenge (Table 1).

A total of five FIVΔRT-vaccinated cats from which virus had been isolated at both 6 and 9 weeks postchallenge became negative at 12 weeks postchallenge, including two cats coinoculated with IFN-γ DNA. These cats remained consistently seropositive, confirming their infected status.

Reduced levels of virus and proviral DNA in peripheral blood of FIVΔRT vaccinates. Since there was evidence of lower viral loads in the FIVΔRT vaccinates, with inconsistent virus isolation results and delayed seroconversion in some cats, we measured the infectious-virus burdens in peripheral blood at 7 and 12 weeks postchallenge. Analysis of the results (Fig. 8a) demonstrated that at week 7 there was a statistically significant difference between the groups overall (F test, \( P = 0.025 \)). However, none of the groups was statistically significantly different pairwise (two-sample \( t \) test, adjusted for multiple comparisons by permutation). When aggregated to the two groups immunized with FIVΔRT compared with the two control groups, the FIVΔRT vaccinates had a statistically significantly lower log initial number of infected cells per \( 2 \times 10^6 \) PBMC.
than did the controls (Fig. 8a). At week 12, pairwise contrasts between vaccinated and control groups were all statistically significant, with $P < 0.02$ (i.e., FIV\textsuperscript{dRT} compared to IFN-\gamma, FIV\textsuperscript{dRT} compared to no DNA, FIV\textsuperscript{dRT} plus IFN-\gamma compared to IFN-\gamma, and FIV\textsuperscript{dRT} plus IFN-\gamma compared to no DNA). Similar conclusions emerged from quantitative PCR analysis of proviral DNA in PBMC. The results shown in Table 2 represent the results obtained with the env primers, and these correlated closely with parallel assays involving pol primers (data not shown). Although the levels of proviral DNA were low in the control cats following challenge with the F-14 molecular clone, these findings were broadly consistent with our earlier study of cats infected with a low dose of the FIV-PET isolate (32). Despite the low overall levels of DNA and evidence of declining load from weeks 6 to 12, clear differences among the four vaccine groups were evident. All of the control cats immunized with either IFN-\gamma or no DNA scored positive in PCRs with 250 ng of DNA at 6 weeks, compared to only 4 of 10 FIV\textsuperscript{dRT} vaccinates. By 12 weeks postchallenge, only 6 of 10 control cats yielded positive results from 500 ng of DNA compared to 10 of 10 at week 6, indicating that the proviral loads later in infection are decreased. The four cats which remained negative by virus isolation and seronegative by immunoblotting and ELISA gave isolated, transient positive PCR results, three at 6 weeks postinfection and one at 12 weeks. These results indicate that the proviral loads in these cats are close to the detection limit of the assay. Of the remaining six vaccinates, all of which yielded positive results by virus isolation and immunoblotting, a single cat was uniformly negative by PCR, three gave single positive PCR results at week 6 postchallenge, one gave positive results at high DNA concentrations at weeks 6 and 12, and the remaining cat gave positive PCR results at all DNA concentrations tested. It was notable that all of the cats in the group which received FIV\textsuperscript{dRT} and IFN-\gamma became uniformly negative by PCR by 12 weeks postchallenge even at the highest input of 1 \textmu g of DNA.

The FIV\textsuperscript{dRT} immunization schedule can be reduced without apparent loss of efficacy. To investigate whether the lengthy immunization schedule could be reduced without compromising protection, we conducted a second experiment in which two groups of five cats received either FIV\textsuperscript{dRT} plus IFN-\gamma or IFN-\gamma alone at 0, 4, and 8 weeks. As in the first trial, this regimen

![Graphs and images demonstrating CTL responses](image-url)
induced cytolitic activity (data not shown) but no detectable antibody responses by the same series of assays (immunofluorescence, immunoblotting, anti-TM peptide ELISA, and assay for virus-neutralizing antibodies). After challenge at 12 weeks, two of five vaccinates remained seronegative and virus could not be isolated at any of the times tested (Table 1) whereas all of the IFN-\(\gamma\)-alone controls became seropositive and positive by virus isolation, consistent with the results of the first trial. Again, immunoblot analysis corroborated these findings (Fig. 7b). Quantitative measurements of virus in the second trial (Fig. 8b) revealed that at 6 weeks postchallenge, the FIV\(\Delta\)RT-plus-IFN-\(\gamma\) vaccinates developed significantly lower viral loads than did the IFN-\(\gamma\) vaccinates (\(P = 0.027\)). By 9 weeks postchallenge, the viral loads of all of the cats were low and there were no differences between the groups (data not shown).

DISCUSSION

This study demonstrates that protection against FIV infection can be achieved by intramuscular administration of non-replicating FIV DNA. A significant proportion of FIV\(\Delta\)RT vaccinates was protected, and the mean viral loads of the vaccinates were significantly reduced compared to those of the control cats. Similar results were obtained in a second trial in which the immunization schedule was shorter, indicating that the interval between immunizations did not appear to influence the protected status of vaccinated cats.

The mechanism of protection is of great interest, particularly in view of the lack of a detectable humoral immune response in the vaccinates prior to challenge. Our results provide an intriguing parallel with the apparently protected status of individuals exposed to HIV who remain seronegative but have measurable CTL responses (35, 37), suggesting that a potent cellular immune response may be sufficient to confer immunity to infection. The induction of CTL in the absence of a detectable humoral immune response following immunization with the FIV\(\Delta\)RT DNA vaccine is in contrast to the responses observed recently following immunization of chimpanzees with a prospective HIV DNA vaccine (4). Following immunization with a plasmid carrying HIV \(env\) and \(rev\) under the regulatory control of the cytomegalovirus promoter, antibodies specific
for HIV Env were detected in all four immunized animals (4). However, it is notable that even with the protracted immunization regime used to immunize the chimpanzees, there were marked differences in the titers of antibodies induced following immunization. Moreover, three of the four immunized chimpanzees failed to generate a humoral response to the viral Gag protein. In this study, we were unable to detect antibodies specific for either FIV Env or Gag proteins in the cats immunized with either FIVΔRT alone or FIVΔRT in conjunction with IFN-γ. In agreement with our findings, a recent study involving FIV env gene-based DNA vaccines induced either low or undetectable levels of FIV-specific antibodies (31).

The bias toward CTL induction rather than antibody production in response to inoculation with FIVΔRT suggested that intramuscular administration of the FIVΔRT DNA generated primarily a Th1-type immune response. Given that previous studies have demonstrated that it is possible to generate potent cellular and humoral immune responses following immunization of macaques with plasmids expressing the env and gag genes of SIVmac251 (24, 34, 49), there is clearly scope for further optimization of the vaccination schedule. However, the question is then which type of immune response is likely to confer protective immunity to challenge with a lentivirus. The SIVmac251-based DNA vaccine neither protected the immunized macaques from challenge with the homologous virus nor led to a reduction in the viral load of the vaccinates (24). Significantly, the SIVmac251 challenge is a highly pathogenic virus; recent data suggest that the FIV-PET challenge virus used in our study is less pathogenic than the FIV GL-8 strain (21). Similarly, the HIV-1 SF2 challenge virus used in the chimpanzee DNA vaccine trial does not induce disease readily in infected animals (4). Future studies should address whether protective immunity to infection with highly pathogenic strains of FIV (7) can be achieved with DNA vaccines.

CTL activity to FIV Env was shown previously to correlate with long-lived immunity induced by whole inactivated virus vaccines (11). In the present study, there was no clear correlation between the elicitation of Env- or Gag-specific CTL responses in the peripheral blood of vaccinated cats and the protection observed following challenge, since qualitatively similar CTL responses were detected in both protected and unprotected cats within each vaccine group. Future studies will...
address the contribution of CTL responses with other viral specificities in protective immunity and will investigate the sequestration of virus-specific CTLs to the lymphoid organs, which may explain the rather short-lived CTL responses observed in the peripheral blood. It should now be possible to identify the critical targets for the protective immune response by selective gene inactivation. Given that immunization of cats with FIV \textit{env} gene-based DNA vaccines resulted in enhancement of infection following challenge (31), it is possible that regulatory gene products expressed by the FIV\textit{D}RT DNA vaccine contributed to its greater efficacy.

A greater proportion of the cats in the group inoculated with IFN-\textgamma in conjunction with FIV\textit{D}RT was protected following challenge compared to the proportion in the group inoculated with FIV\textit{D}RT alone, suggesting that IFN-\textgamma may have enhanced the protective effect of FIV\textit{D}RT. IFN-\textgamma is a pleiotropic immune regulator which is depressed in progressive HIV infect-

![FIG. 7. Immunoblot analysis performed as described previously (19) on plasma samples taken from cats 12 weeks after challenge. (a) Trial 1 (numbered lanes) and plasma from an FIV-infected and an unvaccinated, uninfected cat as controls (lanes + and –, respectively). One cat in the group immunized with \textit{D}RT (lane 4) and three cats in the group immunized with \textit{D}RT and IFN-\textgamma (lanes 1, 3, and 5) remained antibody negative after challenge. (b) Trial 2 (numbered lanes) and control lanes as in panel a. Two cats (lanes 2 and 4) immunized with \textit{D}RT and IFN-\textgamma remained antibody negative after challenge.

![FIG. 8. Viral loads in trial 1 at 7 weeks postchallenge (a) and in trial 2 at 6 weeks postchallenge (b), expressed as the mean ± 2 standard errors of the mean of the log-transformed maximum-likelihood estimates of the initial number of infected cells present in $2 \times 10^6$ PBMC.]

| TABLE 2. Comparison of viral loads in trial 1 at 6 and 12 weeks postchallenge as measured by quantitative nested PCR |
|-----------------|----------------|-----------------|
| DNA inculom     | Cat            | PCR result (wk 6a) | PCR result (wk 12)a | Seroconversion |
|                 |                | 500 ng | 250 ng | 1,000 ng | 500 ng | 250 ng |           |
| FIV\textit{D}RT | 1              | –      | –      | –        | –      | –      | –        |
|                 | 2              | –      | –      | –        | –      | –      | –        |
|                 | 3              | –      | –      | –        | –      | –      | –        |
|                 | 4              | –      | –      | –        | –      | –      | –        |
|                 | 5              | +      | –      | –        | +      | +      | –        |
| FIV\textit{D}RT + IFN-\textgamma | 1 | – | – | – | – | – | – |
|                 | 2              | –      | –      | –        | –      | –      | –        |
|                 | 3              | +      | –      | –        | –      | –      | –        |
|                 | 4              | –      | +      | –        | –      | –      | –        |
|                 | 5              | NDb   | +      | –        | –      | –      | –        |
| IFN-\textgamma | 1              | +      | +      | +        | +      | +      | +        |
|                 | 2              | +      | +      | +        | +      | +      | +        |
|                 | 3              | +      | +      | +        | +      | +      | +        |
|                 | 4              | +      | +      | +        | +      | +      | +        |
|                 | 5              | +      | +      | +        | +      | +      | +        |
| No DNA         | 1              | +      | +      | +        | +      | +      | +        |
|                 | 2              | +      | +      | +        | +      | +      | +        |
|                 | 3              | +      | +      | +        | +      | +      | +        |
|                 | 4              | +      | +      | +        | +      | +      | +        |
|                 | 5              | +      | +      | +        | +      | +      | +        |

* Positive scores denote a positive amplification in one or more aliquots. Serological responses were determined 12 weeks after challenge by immunoblotting, as shown in Fig. 7.

b ND, not done.
tion and has been reported to be inversely correlated with lymph node virus load in primary SIV infection of macaques (23). Although recombinant IFN-γ is being investigated widely as a therapeutic agent (15), its use as a gene adenovirus has been limited so far. Interestingly, replacement of the nef gene in infectious SIVmac with a human IFN-γ gene was recently found to cause further attenuation of the virus and to enhance protection against superinfection with virulent virus (14). Whether these effects are mediated by specific or nonspecific immune mechanisms remains to be determined.

Our results raise wider questions about the role of antibodies in natural and vaccine immunity to lentiviruses. Hitherto, our assumption has been that vaccines should stimulate the broadest possible range of effector mechanisms, and our previous studies with whole inactivated FIV vaccines demonstrated that neutralizing antibodies correlated with protection (16). However, previous studies have described enhancement of FIV infection following immunization with prospective vaccines, including subunit vaccines and a DNA vaccine expressing a limited range of FIV gene products (20, 31, 40). Further studies are necessary to account for the different outcomes of these vaccine experiments compared to the present study and to allow extrapolation of these findings to other immunosuppressive lentiviruses such as HIV in human beings.

ACKNOWLEDGMENTS

This work was supported by the U.K. Medical Research Council and the EC Concerted Action, FAVEUR. T. Miyazawa received a fellowship from the EC Concerted Action, FAVEUR. T. Miyazawa received a fellowship from the EC Concerted Action, FAVEUR. T. Miyazawa received a fellowship from the EC Concerted Action, FAVEUR.

REFERENCES


